PD-L1 Testing and Biomarkers of Response to Immunotherapy in Head and Neck Cancer
Head and neck squamous cell carcinoma (HNSCC) is a worldwide public health problem and, until recently, cancer patients have had limited effective treatment options. For the first time in 50 years, overall survival is being impacted in HNSCC patients with FDA approval of anti-PD-1 therapy. However, only a small subset of HNSCC patients derives clinical benefit. Our meeting will be focused on biomarker testing in head and neck cancer in the setting of immunotherapy given the recent approval of a companion diagnostic in the first line setting treatment of head and neck cancer. Attendees will consist of an international audience of community and academic clinicians, researchers, residents, post-graduate fellows, and medical students. The size of this meeting creates an ideal opportunity for young participants to meet and interact with key opinion leaders in the field, and may lead to long-lasting collaborative and mentoring relationships.
This activity is intended for academic and community medical oncologists, head and neck surgeons, radiation oncologists, pathologists, nurse practitioners, nurses, fellows, residents, and medical students.
Upon completion of this activity, learners will be able to:
- Discuss three pivotal clinical trials that have changed, or will be implementing change in the stand of care for head and neck cancer patients.
- Summarize the various scoring methods (TPS versus CPS) to establish PD-L1 status.
- List three (3) biomarkers of response to immunotherapy identified in head and neck cancer patients
MGH Departments of Surgery and Otolaryngology - Head & Neck Surgery, Massachusetts Eye & Ear - A Harvard Medical School Affiliate, and Partners HealthCare System
To Be Finalized
To Be Finalized
Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for Physicians.
Partners HealthCare System designates this live activity for a maximum of 11.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 11.25 AMA PRA Category 1 Credit™
- 11.25 Participation
In accordance with the American with Disabilities Act, our Course Coordinator can assist you with any special needs (i.e., physical, dietary, etc). Please contact Ms. Kayla Roche prior to the live event at 617-726-5251.
|Industry: individuals affiliated with pharmaceutical companies||$200|
|Patients||Free of Charge|
|Professionals: individuals affiliated with hospitals, universities, or private practices||$50 (default)|
|Residents & Medical Students||Free of Charge|
If you are interested in staying at the Liberty Hotel, please use the following link to book your accommodations: https://www.marriott.com/event-reservations/reservation-link.mi?id=1573161709481&key=GRP&app=resvlink
Registrations cancelled on or before March 13, 2020 will be refunded, less a $20 administrative fee. Registrations cancelled after March 13, 2020 will not be refunded.
contact email@example.com if you require assistance in cancelling your online registration.
The EthosCE standard install will support the two most recent stable releases of the following browsers for all public pages, both authenticated users and anonymous: Edge, Firefox, Google Chrome, Safari, Firefox. EthosCE supports these browsers by default. Other browsers may work also; however, non-listed browsers are not officially supported.